Wave Life Sciences
73 hedge funds and large institutions have $780M invested in Wave Life Sciences in 2017 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 18 increasing their positions, 25 reducing their positions, and 7 closing their positions.
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
75% more capital invested
Capital invested by funds: $446M → $780M (+$334M)
26% more funds holding
Funds holding: 58 → 73 (+15)
6.16% more ownership
Funds ownership: 73.82% → 79.98% (+6.2%)
28% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$25M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$20.7M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$16M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.3M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$20.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.8M |
| 4 |
DM
Deerfield Management
New York
|
-$7.74M |
| 5 |
NLVP
New Leaf Venture Partners
New York
|
-$5.83M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MSU
76
Mizuho Securities USA
New York
| – | -$1.09M | -50,000 | Closed |
|
77
Millennium Management
New York
| – | -$962K | -44,241 | Closed |
|
|
JG
78
Jefferies Group
New York
| – | -$502K | -23,097 | Closed |
|
|
NFA
79
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$146K | -6,720 | Closed |
|
|
MAM
80
Meeder Asset Management
Dublin,
Ohio
| – | +$58 | +2 | New |
|
WVE Hedge Fund Activity: Q4 2017 in Review
73 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Wave Life Sciences (WVE) for Q4 2017, worth a combined $780M — up 75% from $446M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new WVE positions and 7 closed out — a net gain of 15 holders — while 18 added to existing stakes and 25 trimmed.
The largest buyer was BB Biotech, opening a new position worth an estimated $25M. The largest seller was Foresite Capital Management III, cutting an estimated $20.4M.
- 73 institutional investors held Wave Life Sciences (WVE) as of Q4 2017, up from 58 in Q3 2017.
- Funds reported $780M of Wave Life Sciences stock for Q4 2017, up 75% quarter-over-quarter.
- 22 funds opened new Wave Life Sciences positions in Q4 2017 and 7 closed out, a net change of +15 holders.
- The largest Wave Life Sciences buyer in Q4 2017 was BB Biotech, an estimated $25M added.
- The largest Wave Life Sciences seller in Q4 2017 was Foresite Capital Management III, an estimated $20.4M sold.
Based on aggregated 13F filings for Q4 2017.